Barrow Neurological Institute in Phoenix, Arizona, is seeking participants for a Phase II clinical trial of a drug that’s already FDA-approved for multiple sclerosis. The study will evaluate whether siponimod can slow Alzheimer’s progression and determine whether there are new or different side effects in the Alzheimer’s patient population.
This is a small study with 105 participants. You need to attend 9 clinic visits in Phoenix.
For additional information, please visit the siponimod clinical trial.
Greg Rowland’s Alzheimer’s Journey is dedicated to honest reflection and thought-provoking opinions. While we build this publication into a self-sustaining platform through donations, you can support our sustainability plan via our GoFundMe. Reading, subscribing, and sharing this work with others is equally appreciated. Thank you for walking this road with us.
Support Greg Rowland’s Alzheimer’s Journey